Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

GenVec begins phase I clinical trial with TNFerade

Feb. 16, 2001

Merck's new oligopeptide-cytotoxic agent conjugates useful for Rx of cancer, BPH

Feb. 16, 2001

Maxim receives SBIR grants for evaluation of anticancer agents

Feb. 16, 2001

SuperGen obtains certain rights to VTA technology

Feb. 16, 2001

Onconase receives orphan medicinal product designation in Europe

Feb. 15, 2001

Antitumor agents derived from UCF-116 result from Kyowa Hakko-Lilly collaboration

Feb. 15, 2001

Two of British Biotech's MMPIs show no advantage over placebo

Feb. 15, 2001

Licensing opportunity from NIH: NSAID-related gene with antitumorigenic properties

Feb. 15, 2001

Ilex Oncology acquires Symphar; Symphar becomes Ilex Research-Europe

Feb. 14, 2001

Genta's Genasense enters phase III evaluation for multiple myeloma

Feb. 14, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...
Other news to note for July 22, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...